Pulmonx Corporation(LUNG)Earnings, Financials & Key Ratios

LUNG•NASDAQ

$1.48

Price updated Jul 6, 2026

SectorHealthcare IndustryMedical Devices Sub-IndustryRespiratory and sleep therapy devices

AboutPulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.Show more

Revenue$90M+8.0%
EBITDA-$53M+6.2%
Net Income-$54M+4.2%
EPS (Diluted)-1.33+7.6%
Gross Margin74.19%+0.3%
EBITDA Margin-58.13%+13.2%
Operating Margin-59.3%+13.9%
Net Margin-59.67%+11.3%
ROE-77.19%-39.7%

LUNG Price & Volume

Pulmonx Corporation (LUNG) stock price & volume — 10-year historical chart

Loading chart...

Persistent Operating Losses Challenge Pulmonx Growth Trajectory

Investment Thesis • Updated 2026Q1

VerdictNegative

Growth:Decelerating

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Capital dependency and dilution

Key Thesis Takeaways

Pulmonx faces a critical inflection point as revenue growth has decelerated into a 8.7% contraction in 2026Q1, signaling potential saturation or adoption headwinds for its Zephyr Valve system.
Despite maintaining robust gross margins of 77.9%, the company's inability to scale operating expenses—evidenced by a -62.9% operating margin—continues to erode shareholder equity.
Investors should monitor the company's tightening liquidity position, as cash reserves have declined to $61.6 million while the debt-to-equity ratio has climbed to 1.23.

Verdict Logic

the company's inability to achieve operating leverage, combined with a 8.7% revenue decline and a shrinking equity base of $45.8 million, suggests significant execution risk and potential future dilution.

LUNG Growth Metrics

Pulmonx Corporation (LUNG) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years22.55%

3 Years19.03%

TTM1.23%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM6.8%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM9.72%

Return on Capital

10 Years-60.81%

5 Years-34.06%

3 Years-40.09%

Last Year-43.34%

Peers Comparison

Key metrics vs top competitors for Pulmonx Corporation (LUNG)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
LUNGPulmonx CorporationCurrent	$1.48	$62.51M	-1.11	8.01%	-59.67%	-77.19%	—
INSPInspire Medical Systems, Inc.	$49.45	$1.42B	10.11	13.6%	14.33%	17.98%	—
NVCRNovoCure Limited	$17.32	$1.97B	-14.20	8.28%	-25.66%	-50.82%	—
ATRCAtriCure, Inc.	$32.39	$1.64B	-134.96	14.88%	-0.83%	-0.95%	—
PRCTPROCEPT BioRobotics Corporation	$21.21	$1.21B	-12.33	37.22%	-31.82%	-27.7%	—
MMSIMerit Medical Systems, Inc.	$71.45	$4.26B	33.54	11.66%	9.03%	8.95%	—